106 filings
Page 2 of 6
6-K
gh2ptii6h1jd7sb8r 1s
6 Jul 23
Current report (foreign)
8:11am
6-K
go9qvnev
6 Jul 23
Current report (foreign)
7:59am
6-K
u367bsq5bs6amnp
3 Jul 23
Current report (foreign)
4:15pm
6-K
horgqq3qnh7ci7bxfnc
22 Jun 23
Aslan Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab In Japan
8:32am
6-K
1rzqvf9x 1q2m0r4k
28 Apr 23
Aslan Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:29am
6-K
7pgg5rqy
24 Mar 23
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
7:02am
6-K
6prisgqe
10 Mar 23
Aslan Pharmaceuticals Announces Plan to Implement Ads Ratio Change
7:30am
6-K
tni8zs
24 Feb 23
Unit Purchase Agreement
10:27am
6-K
5ph60uohsotoz89gdlp
31 Jan 23
Current report (foreign)
6:02am
6-K
xnia37yg
4 Jan 23
Current report (foreign)
6:02am
6-K
7kjx lwoe8
21 Dec 22
Current report (foreign)
6:03am
6-K
es1f8nv0 x9ak26
28 Oct 22
Aslan Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:01am
6-K
751t7zcrg6bdhv
28 Sep 22
Current report (foreign)
9:01am
6-K
08z6ahrl lpdw9lx0fh
14 Sep 22
Current report (foreign)
7:45am
6-K
5lpdly4
13 Sep 22
Amendment No. 1 to the Open Market Sale Agreementsm
4:31pm
6-K
3j4vzgzm9g8
8 Sep 22
Current report (foreign)
7:01am
6-K
imvws11dco4av94t
12 Aug 22
Aslan Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
6:54am
6-K
xlt09rwnwde l0wpxn4d
27 Apr 22
Aslan Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:00am
6-K
t05ge6qwbc8h04rc7t
1 Apr 22
Aslan Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
5:00pm
6-K
c9hjaqwa13v
25 Mar 22
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
7:05am